Malin (MLC) H1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2025 earnings summary
8 Sep, 2025Executive summary
Estimated intrinsic equity value was €41.3 million as of 30 June 2025, reflecting the fair value of investee companies and cash.
Intrinsic equity value per share was €9.52 at 30 June 2025.
Financial highlights
Cash position stood at €13.7 million as of 30 June 2025.
By 25 August 2025, estimated intrinsic equity value slightly decreased to €41.0 million.
Cash balance as of 25 August 2025 was €13.4 million.
Intrinsic equity value per share was €9.45 as of 25 August 2025.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Malin
- Intrinsic equity value fell 12% by August 2026, mainly due to Kymab's contingent write-down.MLC
H1 2026 - Portfolio of innovative life sciences assets targets near-term value creation and shareholder returns.MLCInvestor presentation
- Intrinsic equity value per share increased to €9.24, with major leadership changes and capital return.MLCH2 2025
- Cash surges to €62.9m post-CG Oncology sale; €45m capital return planned for shareholders.MLCH1 2024
- Major divestments drove a €150m capital return and record cash reserves for Malin in 2024.MLCH2 2024